Tumor Models
WuXi Biology has a significant experience in oncology drug discovery. We offer a large collection and tumors model for small & large molecule drug discovery.
- A large collection of cell line-derived xenograft (CDX) tumor models with an imaging based orthotopic/metastatic CDX platform covering 16 tumor types
- Patient-derived xenograft (PDX) tumor models covering 20 cancer types, drug resistant model and mouse clinical trial enabling translational research
- Syngeneic tumor models covering 20 cancer types, enabled with immunotherapy SOC, TIL analysis and RNAseq profiling.
- Human immune checkpoint gene KI mouse models
- hPBMC/HSC humanized models
- Extensive panel of c-MET related CDX and PDX tumor models
Cell line-derived xenograft (CDX) tumor models
- 320+ validated models covering 30 tumor types
- 77+ cell lines derived from PDX models
- Available data of sensitivities to SOC (standard of care)
- Imaging-based orthotopic/metastatic tumor models
- Brain/bone metastatic models of lung/breast cancer cell lines


41 Luciferase Labelled Orthotopic/Metastatic Tumor Models
- Covering 17 tumor types
- Bioluminescent imaging system in SPF barrier

Patient-derived xenograft (PDX) tumor models
- 1,400+ PDX models covering full range of cancer types
- Fully-characterized models with genetic, molecular and pharmacological profiling
- Drug-resistant models, including a clinical acquired capmatinib-resistant LU-01-0751 lung cancer PDX model
- in vitro screening and derivative PDXC/PDXO models
- IO-PDX panel with hPBMC humanization

A Comprehensive PDX Collection of Asia Prevalent Tumors with Genomic Profiling

Syngeneic tumor models
- 87 Syngeneic models (mouse, rat, hamster) covering 20 cancer types
- Comprehensive panel of orthotopic syngeneic tumor models
- Responsiveness to immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4, etc.)
- Tumor-infiltrating leukocytes (TILs) map
- WES, RNA-seq and scRNA-seq characterization

Genetically engineered models
- 48 engineered cell lines based on construct overexpression or gene knock-in
- Pharmacologically validated both in vitro and in vivo
- Focusing on drug-resistant mutation introduction and IO-related checkpoint humanization
- Example targets: EGFR, ROS1, ALK, RET, FLT3, BTK, Claudin18.2, PD-L1
hPBMC/HSC Humanized Models
hPBMC Humanized Models
- Established models for immune-checkpoint inhibitor and bi-specific antibody candidates in a human-resembling immune system.
- Annotation for both immune cells (phenotyping, biomarker, functions) and tumor cells (expression, mutation)
- Different PBMC delivery systems (systemic injection or co-inoculation with tumor)
HSC Humanized Models
- Available humanized models from CIEA, combined with WuXi PDX/CDX models.
- Customizable with human cytokine transgenic mice (GM-CSF/hIL-3 or hIL-2) to improve the reconstitution of myeloid lineage.
Established CDX/PDX-hPBMC Models

Human immune checkpoint gene KI mouse models
KI (Knock-in) mice offer the possibility to study clinical grade checkpoint antibodies targeting human checkpoints in the context of a fully functional immune system. WuXi Biology offers efficacy studies in different mouse strains with human targets KI in mice and cell line, and comprehensive flow cytometry to evaluate target expression and immune function.
- Collection of various targets and background mouse strains
- Validated with launched or most advanced clinical grade checkpoint antibodies
- Double checkpoint KI mice customizable for combination (PD1 + OX40, PD1 + TIM3)

Immuno-avatar humanized models
- Mouse models harboring human tumor and human immune ceils
- Three different diagram of hPBMC humanization for mature T cell engraftment
- HSC (CD34+) avatar and next generation immune avatar for multiple-lineage engraftment (Myeloid, NK, DC)
- IO-CDX and IO-PDX models with cancer targets and HLA information
Drug-resistant models
- Engineered cell line derived xenograft models
- Acquired drug-resistant CDX and PDX models
- Intrinsic drug-resistant PDX models
- Resistant models harboring specific oncogenic drivers
- KRAS G12C drug resistant tumor models
- Extensive panel of CDK4/6 inhibitor resistant breast cancer models
- Clinical acquired capmatinib-resistant LU-01-0751 lung cancer PDX model
- Enzalutamide-resistant (LNCAP AR-F877L) mutation KI prostate cancer model
- Drug-resistant cell lines and corresponding in vivo models using CRISPR-mediated knock-in technology (for targets including BTK and ESR1)
Related Resources View All
OncoWuXi Express: In vitro and in vivo evaluation of an...
Resource Type: Article Case Study
Metastasis-Related In Vitro Assays and Xenograft Models
Resource Type: Latest Science Presentation
Oncolytic Virus Platform
Resource Type: Latest Science Presentation
Evaluation Platform for Bispecific Antibodies
Resource Type: Latest Science Presentation
Enzalutamide-resistant LNCaP ARF877L Mutation KI model
Resource Type: Latest Science Presentation
Tumor Cell Panel | Screening Services
Resource Type: Brochure
Orthotopic and Metastasis Syngeneic Models
Resource Type: Latest Science Presentation
DLL3-Related PDX Models
Resource Type: Latest Science Presentation
c-MET Related In Vivo Models
Resource Type: Latest Science Presentation
AACR 2023: Integrated platform enables KRAS-targeted drugs discovery
Resource Type: Poster
AACR 2023: Therapeutic potential of polatuzumab vedotin for the treatment...
Resource Type: Poster
AACR 2023: A tailored platform enables BRAF-targeted drug discovery and...
Resource Type: Poster
BRAF-Related In Vivo Models
Resource Type: Latest Science Presentation
Xenograft and Syngeneic Tumor Models in Rats
Resource Type: Latest Science Presentation
Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines
Resource Type: Latest Science Publication
KRAS-related Genetically Engineered Cell Lines and In Vivo Models
Resource Type: Latest Science Presentation
CDK4/6 Inhibitor Resistant Breast Cancer Models
Resource Type: Latest Science Presentation
How Does It Work? | Antibody Drug Conjugates
Resource Type: Video
WuXi AppTec Discovery Services
Resource Type: Brochure
Brain metastasis mouse models for the evaluation of multikinase inhibitors...
Resource Type: Poster
Intra-carotid artery brain metastasis models for the evaluation of lung...
Resource Type: Poster
Developing drug-induced resistant tumor models for efficacy evaluation of next-generation...
Resource Type: Poster
Developing a panel of orthotopic syngeneic tumor models for IO...
Resource Type: Poster
Development of an integrated in vitro and in vivo OVA-specific...
Resource Type: Latest Science Poster
Mouse hind limb tumor metastatic model to evaluate prophylaxis and...
Resource Type: Latest Science Poster
Establishment of spatial transcriptomics assay to find the mechanism of...
Resource Type: Latest Science Poster
Evaluating cancer therapies combining radiotherapy with immunotherapy or inhibitors of...
Resource Type: Latest Science Poster
Tumor evolution selectively inactivates the core microRNA machinery for immune...
Resource Type: Latest Science Publication
Evaluation of the efficacy of ADC in vitro and in...
Resource Type: Poster
Immuno-Oncology Platform to Enable Discovery from Target to Drug
Resource Type: Presentation Video
Validation of GVHD in mouse model for preclinical efficacy screen
Resource Type: Poster
Engineered cell line panel complemented with in vivo models to...
Resource Type: Poster
Establishment of drug induced resistant tumor models enable the development...
Resource Type: Poster
Establishment of KRAS-G12C inhibitor induced resistant tumor models enable the...
Resource Type: Poster
Translational Oncology
Resource Type: Brochure
Patient-Derived Xenograft (PDX) Tumor Models
Resource Type: Brochure
Immuno-Oncology Services
Resource Type: Brochure
Cell Line-Derived Xenograft (CDX) Tumor Models
Resource Type: Brochure
WuXi Oncology and Immuno-Oncology Services
Resource Type: Brochure
Hepatocellular Carcinoma (HCC) Models
Resource Type: Brochure